Less than 10% of people with type 2 diabetes who are eligible will buy the expensive new drug.

Published Date: 02 Mar 2023

Data from 1,133 US adults with type 2 diabetes revealed that only 9% were treated with an SGLT2 inhibitor or GLP-1 agonist in 2017-2020, even though they all met the 2022 criteria. .

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.

2.

GuCS: Genitourinary Cancers Symposium

3.

Obesity-associated cancers tripled nationwide over past two decades

4.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

5.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot